<DOC>
	<DOC>NCT02695004</DOC>
	<brief_summary>This is a study to evaluate safety, tolerability and PK of DKF-310 IM injection in healthy male volunteers.</brief_summary>
	<brief_title>Safety, Tolerability and Pharmacokinetics of DKF-310 ( (Donepezil).</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Donepezil</mesh_term>
	<criteria>Men aged 19 to 50 years Body weight 55 to 90 kg and BMI 18.0 to 27.0 Voluntarily signed the informed consent form Eligible according to the screening test results Available to follow up after dropout Clinically significant disorders or a medical history of hepatic, renal, neurological, respiratory, endocrine, hematooncologic, cardiovascular, urological and psychiatric diseases Hypersensitivity to donepezil, piperidine derivatives and other drugs SBP &lt;100 mmHg or &gt;150 mmHg, or DBP &lt;60 mmHg or &gt;100 mmHg Skin and muscle disorders or history of surgery at the injection site AST or ALT &gt;1.5xULN; QT/QTcB interval &gt;450 ms History or positive result of drug abuse Prescribed drugs or herbal medicines within 2 weeks, overthecounter drugs or vitamins within 1 week Participated in other clinical trials within 3 months Donated whole blood within 2 months or apheresis within 1 month, or transfusion within 1 month Alcohol consumption &gt;21 units/week Smoked &gt;10 cigarettes/day within 3 months Caffeinecontaining foods Not eligible due to other reasons at the investigator's discretion</criteria>
	<gender>Male</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>